Ventricular tachycardia cost effectiveness of therapy
Overview
Overview
Based on a randomized clinical trial evidence, Catheter ablation of VT is unlikely to be cost-effective compared with antiarrhythmic drug (AAD) therapy. However, more detailed and better designed studies are needed to provide more informed cost-effectiveness analyses.
Cost effectiveness of therapy
Cost effectiveness of therapy
Evidence from a randomized clinical trial has shown that Catheter ablation of VT is unlikely to be cost-effective compared with antiarrhythmic drug (AAD) therapy. However, better designed studies with more details and more frequent quality of life assessments are required to provide more informed cost-effectiveness analyses[1]
References
References
- ↑ Chen Y, Gomes M, Garcia JV, Hunter RJ, Chow AW, Dhinoja M; et al. (2020). “Cost-effectiveness of ablation of ventricular tachycardia in ischaemic cardiomyopathy: limitations in the trial evidence base”. Open Heart. 7 (1): e001155. doi:10.1136/openhrt-2019-001155. PMC 6999675 Check
|pmc=value (help). PMID 32076562 Check|pmid=value (help).
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH